Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology · 2025
DOI: 10.1016/j.cgh.2024.07.013 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Sung Won Chung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Liver Center, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Tenofovir, Hepatitis B, Chronic, Antiviral Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Korean Association for the Study of the Liver, National Research Foundation of Korea, Asan Medical Center Asan Institute for Life Sciences.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Whether tenofovir or entecavir has different effects on the prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) in secondary and tertiary preventive settings is still a matter of debate. This study aimed to compare the long-term prognosis of HCC between tenofovir and entecavir in patients with chronic hepatitis B. METHODS: Chronic hepatitis B patients diagnosed with HCC between November 2008 and December 2018 and treated with either entecavir or tenofovir at a tertiary center in Korea were included. The effect of tenofovir compared with entecavir on the prognosis of HBV-related HCC was assessed using multivariable-adjusted Cox and propensity score (PS)-matched analyses. Various predefined subgroup analyses were conducted. RESULTS: During a median follow-up period of 3.0 years, the mortality rate for entecavir-treated patients (n = 3469) was 41.2%, while tenofovir-treated patients (n = 3056) had a mortality rate of 34.6%. Overall survival (OS) was better in the tenofovir group (adjusted hazard ratio [aHR], 0.79; P < .001), which were consistently observed in the PS-matched analysis. The magnitude of the risk difference in OS was more prominent 2 years after the diagnosis of HCC (aHR, 0.50; P < .001) than 2 years before (aHR, 0.88; P = .005), and it was more pronounced in patients with earlier HCC stages. In all subgroups, except for those with shorter life expectancy, such as those with compromised liver function, tenofovir was associated with better OS compared with entecavir. CONCLUSIONS: Among patients with HBV-related HCC, those treated with tenofovir had a better prognosis than those treated with entecavir, particularly among those with prolonged survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Center, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Liver Center, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: dr.choi85@gmail.com.
Förderung
- Korean Association for the Study of the Liver
- National Research Foundation of Korea
- Asan Medical Center Asan Institute for Life Sciences
Zitieren
APA
Chung, S. W., Um, H. J., Choi, W. M., Choi, J., Lee, D., Shim, J. H., Kim, K. M., Lim, Y. S., & Lee, H. C. (2025). Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.07.013
Vancouver
Chung SW, Um HJ, Choi WM, Choi J, Lee D, Shim JH, et al. Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.07.013
BibTeX
@article{Chung2025,
author = {Chung, Sung Won and Um, Hyun Jun and Choi, Won-Mook and Choi, Jonggi and Lee, Danbi and Shim, Ju Hyun and Kim, Kang Mo and Lim, Young-Suk and Lee, Han Chu},
title = {Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
doi = {10.1016/j.cgh.2024.07.013}
}
EUVIMED